

Clark & Elbing LLP

101 Federal Street
Boston, MA 02110

Telephone 617-428-0200
Facsimile 617-428-7045
617-428-7046

Date: June 1, 2009

To: Examiner Meera Natarajan
U.S. Patent and Trademark Office
Group Art Unit 1643

Facsimile No.: 571-270-4058

From: Jan N. Tittel, Ph.D.
Reg. No. 52,290

Re: U.S. Patent Application Serial No. 10/579,147
ANTI-IDIOTYPE ANTIBODIES OF THE HUMAN
MONOCLONAL ANTIBODY SC-1, AND THEIR PRODUCTION
AND USE
Heinz Peter Vollmers et al.
Filed March 19, 2007
Attorney Docket No. 50274/015002
Customer No. 21559
Confirmation No. 3661


Pages: 2, including cover page.

Message: The following papers are enclosed:

Proposed amendment to claim 5 discussed telephonically on June 1,
2009 (1 page).

Non-elected claims 7-11 have been canceled.

Please contact the undersigned with any questions at 617-428-7050.



Jan N. Tittel, Ph.D.
Registration No. 52,290

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

Attorney Docket No. 50274/015002

U.S.S.N. 10/579,147

ANTI-IDIOTYPE ANTIBODIES OF THE HUMAN MONOCLONAL ANTIBODY SC-1, AND THEIR PRODUCTION AND USE

PROPOSED CLAIM AMENDMENT

1-2. (Cancelled).

3. (Original) Hybridoma cell line with DSMZ accession number DSM ACC2625.

4. (Original) The anti-idiotypic antibody expressed by the hybridoma cell line of claim 3.

5. (Currently Amended) A humanized antibody having the binding specificity of the anti-idiotypic antibody of claim 4, wherein said humanized antibody is a humanized version of the antibody expressed by the hybridoma cell line with DSMZ accession number DSM ACC2625.

6. (Original) The anti-idiotypic antibody of claim 4, wherein said anti-idiotypic antibody further comprises a detectable agent.

7-28. (Cancelled).

29. (Previously Presented) A humanized anti-idiotypic antibody having the 6 CDRs of the anti-idiotypic antibody expressed by the hybridoma cell line with DSMZ accession number DSM ACC2625, wherein the humanized anti-idiotypic antibody specifically binds a polypeptide comprising the SC-1 human monoclonal antibody heavy chain sequence set forth in SEQ ID NO: 1.

30. (Previously Presented) The humanized anti-idiotypic antibody of claim 29, where said antibody further comprises a detectable agent.

31. (Previously Presented) A method of generating an immune response in a mammal against the anti-idiotypic antibody of claim 29, said method comprising immunizing a mammal with the purified antibody of claim 29 in a pharmaceutically acceptable carrier.